Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:2265:223-233.
doi: 10.1007/978-1-0716-1205-7_17.

PD-L1 Detection on Circulating Melanoma Cells

Joseph W Po  1   2   3 , Yafeng Ma  4   5   6 , Bavanthi Balakrishnar  7 , Daniel Brungs  4   5   8   9 , Farhad Azimi  7 , Adam Cooper  5   10   7 , Erin Saricilar  10   6   7   11 , Vinay Murthy  4   5   10   7 , Paul de Souza  4   10   6   7   8 , Therese M Becker  4   5   10   6
Affiliations

PD-L1 Detection on Circulating Melanoma Cells

Joseph W Po et al. Methods Mol Biol. 2021.

Abstract

The advent of personalized medicines targeting cell signaling pathways has radically improved melanoma patient outcomes. More recently, immune-modulating therapies disrupting the PD-1/PD-L1 axis have become a powerful tool in the treatment of a range of melanoma, showing a profound improvement in the overall survival outcomes. However, immune checkpoint inhibitors (ICIs) are associated with considerable toxicities and appear to only be efficacious in a subset of melanoma patients. Therefore, there is an urgent need to identify biomarkers that can determine if patients will or will not respond to ICI therapy. Here, we describe an optimized method for analyzing PD-L1 expression on circulating melanoma cells following immunomagnetic enrichment from patient blood samples.

Keywords: Circulating tumor cells (CTC); Immunotherapy; Liquid biopsy; Melanoma; PD-L1.

PubMed Disclaimer

References

    1. Ding PN, Becker TM, Bray VJ, Chua W, Ma YF, Lynch D, Po J, Luk AWS, Caixeiro N, de Souza P, Roberts TL (2019) The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a prospective study. Lung Cancer 134:187–193. https://doi.org/10.1016/j.lungcan.2019.06.021 - DOI - PubMed
    1. Lim M, Kim CJ, Sunkara V, Kim MH, Cho YK (2018) Liquid biopsy in lung cancer: clinical applications of circulating biomarkers (CTCs and ctDNA). Micromachines (Basel) 9(3):100. https://doi.org/10.3390/mi9030100 - DOI
    1. Alix-Panabieres C, Pantel K (2016) Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6(5):479–491. https://doi.org/10.1158/2159-8290.CD-15-1483 - DOI - PubMed
    1. Becker TM, Caixeiro NJ, Lim SH, Tognela A, Kienzle N, Scott KF, Spring KJ, de Souza P (2014) New frontiers in circulating tumor cell analysis: a reference guide for biomolecular profiling toward translational clinical use. Int J Cancer 134(11):2523–2533. https://doi.org/10.1002/ijc.28516 - DOI - PubMed
    1. Hwang WL, Pleskow HM, Miyamoto DT (2018) Molecular analysis of circulating tumors cells: biomarkers beyond enumeration. Adv Drug Deliv Rev 125:122–131. https://doi.org/10.1016/j.addr.2018.01.003 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources